# Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

> **NCT00097968** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Graft Rejection

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT00097968
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097968, "Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00097968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*